Nagendran Sukumar's Insider Trades & SAST Disclosures
Nagendran Sukumar's most recent trade in Taysha Gene Therapies Inc was a trade of 324,500 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 2, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Nagendran Sukumar.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 324,500 | 324,500 | - | - | Employee Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 324,500 | 1,222,343 | - | 0 | Common Stock | |
| Solid Biosciences Inc | Sukumar Nagendran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 34,400 | 34,400 | - | - | Director Stock Option (Right to Buy) | |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 863,617 | 897,843 | - | 0 | Common Stock | |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 863,617 | 863,617 | - | - | Employee Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Nagendran Sukumar | Director, President and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2023 | 334,005 | 334,005 | - | - | Employee Stock Option (right to buy) | |
| Solid Biosciences Inc | Sukumar Nagendran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 9,650 | 9,650 | - | - | Director Stock Option (Right to Buy) | |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Purchase of securities on an exchange or from another person at price $ 0.68 per share. | 16 May 2023 | 5,000 | 34,226 | - | 0.7 | 3,400 | Common Stock |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director, President and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2022 | 790,093 | 790,093 | - | - | Stock Option (right to buy) | |
| Solid Biosciences Inc | Sukumar Nagendran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2022 | 9,650 | 9,650 | - | - | Director Stock Option (Right to Buy) | |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 15,500 | 15,500 | - | - | Stock Option (right to buy) | |
| Solid Biosciences Inc | Sukumar Nagendran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 51,000 | 51,000 | - | - | Director Stock Option (Right to Buy) | |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director | Purchase of securities on an exchange or from another person at price $ 8.01 per share. | 02 Feb 2022 | 10,000 | 29,226 | - | 8.0 | 80,100 | Common Stock |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 15,500 | 15,500 | - | - | Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director | 28 Sep 2020 | 19,226 | 19,226 | - | - | Common Stock | ||
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director | 28 Sep 2020 | 17,647 | 0 | - | - | Series B Preferred Stock | ||
| Taysha Gene Therapies Inc | Sukumar Nagendran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2020 | 31,000 | 31,000 | - | - | Stock Option (right to buy) | |
| Solid Biosciences Inc | Sukumar Nagendran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 30,000 | 30,000 | - | - | Director Stock Option (Right to Buy) | |
| Solid Biosciences Inc | Sukumar Nagendran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 10,000 | 10,000 | - | - | Director Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges